Drug intelligence / Profile preview

CS44032

Development stage: Preclinical
Lead developer: Chipscreen NewWay Biosciences
Modality: Small Molecules

Overview

CS44032 is a preclinical-stage small molecule inhibitor of Bromodomain-containing protein 4 (BRD4), developed by Chipscreen NewWay, a subsidiary of Shenzhen Chipscreen Biosciences. BRD4 is a member of the BET (bromodomain and extra-terminal domain) family and serves as an epigenetic reader that binds to acetylated lysine residues on histones. This binding recruits transcriptional machinery to promote the expression of key oncogenic drivers, such as MYC. By inhibiting BRD4, CS44032 disrupts these transcriptional programs, leading to the downregulation of genes involved in cell cycle progression and survival. The compound is currently being investigated for its potential therapeutic application in various solid tumors.

Targets

BRD4 (Bromodomain-containing protein 4)

Beyond the preview

Go deeper on CS44032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS44032.

Explore the full profile